SCHEMBL3658960

SCHEMBL3658960

CC(Cc1ccccc1)=NO

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTBP2 P56545 1/20 0.52
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 3/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
POLB P06746 1/20 0.47
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
AKR1B1 P15121 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NOS2 P35228 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
TSHR P16473 2/20 0.41
ALOX12 P18054 1/20 0.41
TP53 P04637 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14667472 1.00 CTBP2 (0.52) CTBP2KDM4EALDH1A1KMT2AMEN1
SCHEMBL10177334 1.00 CTBP2 (0.52) CTBP2KDM4EALDH1A1KMT2AMEN1
SCHEMBL25620241 0.83 KDM4E (0.50) CTBP2KDM4EALDH1A1KMT2AMEN1
SCHEMBL11254350 0.82 ALOX5 (0.57) ALDH1A1SMN1; SMN2L3MBTL1CYP2C19HDAC6
SCHEMBL13902884 0.81 KDM4E (0.49) CTBP2KDM4EALDH1A1KMT2AMEN1
SCHEMBL19433078 0.81 KDM4E (0.49) CTBP2KDM4EALDH1A1KMT2AMEN1
SCHEMBL362289 0.79 CTBP2 (0.55) CTBP2ALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL28007823 0.79 CTBP2 (0.52) CTBP2ALDH1A1SMN1; SMN2HDAC8HDAC6
SCHEMBL10889866 0.79 PLAU (0.42) CTBP2KDM4EALDH1A1SMN1; SMN2TP53
SCHEMBL8570445 0.79 KDM4E (0.47) CTBP2KDM4EALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114835660-A Preparation method of oxime ether 浙江理工大学 2022-08-02 CN claimed
CN-110015974-B Preparation method of cyclododecanone oxime 万华化学集团股份有限公司 2022-01-07 CN claimed
CN-107488090-B Efficient catalytic asymmetric preparation method of N-cyclopropyl nitrone compound 东北师范大学 2020-06-02 CN claimed
EP-1527165-A4 A RHODOCOCCUS GENE ENCODING ALDOXIME DEHYDRATASE DU PONT (US) 2006-06-07 EP claimed
EP-1527165-A2 A RHODOCOCCUS GENE ENCODING ALDOXIME DEHYDRATASE E.I. du Pont de Nemours and Company (US) 2005-05-04 EP claimed
WO-2003078581-A2 A RHODOCOCCUS GENE ENCODING ALDOXIME DEHYDRATASE E.I. DU PONT DE NEMOURS AND COMPANY (US) 2003-09-25 WO claimed
JP-3145448-A None JP disclosed
US-11871754-B1 Promoting growth, yield, and salinity tolerance of Achillea fragrantissima King Faisal University (SA) 2024-01-16 US disclosed
US-20230321010-A1 Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms CHEMAPOTHECA, LLC (US) 2023-10-12 US disclosed
US-11717498-B2 Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms Pharmapotheca A, Inc. (US) 2023-08-08 US disclosed
CN-114835660-A Preparation method of oxime ether 浙江理工大学 2022-08-02 CN disclosed
CN-110015974-B Preparation method of cyclododecanone oxime 万华化学集团股份有限公司 2022-01-07 CN disclosed
US-11123310-B2 Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms PHARMAPOTHECA, LLC (US) 2021-09-21 US disclosed
CN-85108668-A The preparation method of diphenyl ether herbicide 1986-05-10 CN disclosed
US-4581365-A Trichloroacryloyl oxime fungicides NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1986-04-08 US disclosed
EP-0112524-A1 Trichloroacryloyl oxime derivatives NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1984-07-04 EP disclosed
EP-0023560-A1 Process for preparing O-substituted ketoximes BASF Aktiengesellschaft (DE) 1981-02-11 EP disclosed
US-4190656-A VIRICIDES, ANTITUMOR AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1980-02-26 US disclosed
US-4176121-A INSECTICIDES, MITICIDES; CYCLIZATION OF METHYL KETONE OXIME WITH A HALOACETYL CHLORIDE, REACTION WITH A THIOPHOSPHORIC OR THIOPHOSPHO STAUFFER CHEMICAL COMPANY (US) 1979-11-27 US disclosed
US-4137308-A 1,3-Oxazole phosphates and phosphonates as insecticides and miticides STAUFFER CHEMICAL COMPANY (US) 1979-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11123310-B2 Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms SLC6A3, CES2, SLC6A2 CTBP2 2479/4885KDM4E 808/4885ALDH1A1 682/4885
US-11717498-B2 Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms SLC6A3, SLC6A2, CES2 CTBP2 2394/4885KDM4E 882/4885ALDH1A1 687/4885
US-20230321010-A1 Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms SLC6A3, CES2, SLC6A2 CTBP2 2357/4885KDM4E 895/4885ALDH1A1 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.